Reports Q2 revenue $29.08M, consensus $28.79M. Dosed first patients in supplemental, 12-patient Japanese cohort in global Phase 3 trial evaluating setmelanotide in hypothalamic obesity; On track for topline data from 120-patient, pivotal cohort in 1H 2025. Cash on-hand expected to support planned operations into 2026.
Protect Your Portfolio Against Market Uncertainty
- Discover companies with rock-solid fundamentals in TipRanks' Smart Value Newsletter.
- Receive undervalued stocks, resilient to market uncertainty, delivered straight to your inbox.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RYTM:
- Rhythm Pharmaceuticals Reports Second Quarter 2024 Financial Results and Business Update
- RYTM Earnings Report this Week: Is It a Buy, Ahead of Earnings?
- Rhythm Pharmaceuticals Announces European Commission Expands ▼IMCIVREE® (setmelanotide) Marketing Authorization to include Children as Young as 2 Years Old
- Rhythm Pharmaceuticals announces expansion of IMCIVREE marketing authorization
- Rhythm announces first patients dosed in Phase 2 trial of LB54640